Interventional study with minimal risks and constraints, with evaluation of the incidence of lung cancers by low-dose thoracic CT scan without injection of contrast medium, of the immunological, inflammatory and metabolic blood profile and of the microbiota; systematic proposal of smoking cessation for active smokers or assistance in maintaining cessation.
1- All PREVALUNG or PREVALUNG ETOILE participants
2- Active or former smokers who have smoked daily for at least 10 years and have either atheromatous disease (coronary, lower limb, supra-aortic trunk, aortic, visceral or upper limb arteries) or a moderate or high coronary calcium score*, **.
Age 45- 75 years and
Medical follow-up for smoking-related atheromatous pathology and
cancer history < 5 years (except carcinoma in situ of the uterine cervix, basal cell carcinoma of the skin, non-invasive urothelial carcinoma treated for curative purposes without CT lung surveillance, prostate cancer with unmeasurable PSA)
symptoms of lung cancer (involuntary weight loss > 7 kg in 1 year, hemoptysis)
known history of pulmonary nodule requiring specialized follow-up
history of pulmonary fibrosis or pulmonary hypertension